Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Safingol |
Synonyms | |
Therapy Description |
Kynacyte (safingol) inhibits protein kinase C (PKC), potentially resulting in increased tumor cell death and increased sensitivity to other anti-cancer agents (PMID: 15929099, PMID: 9815717). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Safingol | Kynacyte|Sphinganine | PKC Inhibitor (Pan) 11 | Kynacyte (safingol) inhibits protein kinase C (PKC), potentially resulting in increased tumor cell death and increased sensitivity to other anti-cancer agents (PMID: 15929099, PMID: 9815717). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01553071 | Phase I | Safingol Fenretinide | Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies | Terminated | USA | 0 |